Orion Group Financial Statement Release for 2019
February 05, 2020 05:00 ET
|
Orion Oyj
ORION CORPORATION FINANCIAL STATEMENT RELEASE 2019 5 FEBRUARY 2020 at 12:00 noon Orion Group Financial Statement Release for 2019 This is a summary or Orion’s Financial...
Euroopan lääkeviraston ihmislääkekomitealta (CHMP) myönteinen lausunto etäpesäkkeettömän, hormonaaliselle hoidolle vastustuskykyisen eturauhassyövän hoitoon tarkoitetulle darolutamidille
January 31, 2020 06:30 ET
|
Orion Oyj
ORION OYJ LEHDISTÖTIEDOTE 31.1.2020 klo 13.30 Euroopan lääkeviraston (EMA) ihmislääkekomitea (CHMP) on antanut myönteisen lausunnon suosittaen darolutamidin myyntiluvan...
Positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer
January 31, 2020 06:30 ET
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 31 JANUARY 2020 at 13.30 EET The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended...
Darolutamidin ja tavanomaisen hormonaalisen hoidon yhdistelmä lisää merkitsevästi etäpesäkkeetöntä kastraatioresistenttiä eturauhassyöpää sairastavien miesten kokonaiselinaikaa
January 30, 2020 01:30 ET
|
Orion Oyj
ORION OYJ LEHDISTÖTIEDOTE 30.1.2020 klo 8.30 Lopulliset kokonaiselinaikaa koskevat tulokset III-vaiheen ARAMIS-tutkimuksesta osoittavat, että darolutamidin ja tavanomaisen hormonaalisen...
Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer
January 30, 2020 01:30 ET
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 30 JANUARY 2020 at 8.30 EET Results from the preplanned final overall survival analysis of the Phase III ARAMIS (Androgen Receptor inhibiting...
Darolutamidille myyntilupa Japanissa
January 23, 2020 01:30 ET
|
Orion Oyj
ORION OYJ LEHDISTÖTIEDOTE 23.1.2020 klo 8.30 Japanin terveysministeriö on myöntänyt darolutamidille myyntiluvan kauppanimellä Nubeqa®. Myyntilupa on myönnetty etäpesäkkeettömän,...
Marketing authorization granted for darolutamide in Japan
January 23, 2020 01:30 ET
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 23 JANUARY 2020 at 8.30 EET The Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for darolutamide,...
Prostate Cancer: Global Drug Forecast and Market Analysis to 2028
November 05, 2019 10:13 ET
|
ReportLinker FR
New York, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Prostate Cancer: Global Drug Forecast and Market Analysis to 2028" -...
Prostate Cancer: Global Drug Forecast and Market Analysis to 2028
November 01, 2019 09:03 ET
|
ReportLinker FR
New York, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Prostate Cancer: Global Drug Forecast and Market Analysis to 2028" -...
Orion Group Interim Report 1–9/2019
October 23, 2019 05:00 ET
|
Orion Oyj
ORION CORPORATION INTERIM REPORT 1-9/2019 JANUARY–SEPTEMBER 2019 23 October 2019 at 12.00 EEST Orion Group Interim Report 1–9/2019 Net sales in January–September 2019 totalled EUR 776...